Calculator Predicts Antihistamine Response in Urticaria
METHODOLOGY:
The tool considers age, angioedema, anxiety/depression, disease duration, hypersensitivity to nonsteroidal anti-inflammatory drugs, and the Urticaria Activity Score (UAS) to predict response to treatment.
To assess its accuracy, the researchers conducted a prospective cohort study involving 542 patients with CSU from Colombia, Ecuador, Peru, and Argentina.
The calculator stratified patients as having a high or low probability of responding to antihistamines.
The researchers used the 7-day UAS to determine clinical response, with a score of 6 or less indicating control of the disease.
TAKEAWAY:
The prognostic model had 78.6% accuracy, the researchers reported.
It correctly predicted 82.9% of the nonresponders and 72.7% of the responders.
The type of antihistamine used did not affect the performance of the model, the researchers found. Medications used in the study included loratadine, cetirizine, levocetirizine, desloratadine, fexofenadine, and bilastine.
IN PRACTICE:
'Predicting the clinical response can help to promptly identify patients who could benefit from the use of alternative therapies and avoid prolonged times when evaluating anti-H1 [antihistamine] therapeutic response (eg, start immediately with the highest dose and prioritize clinical appointment in a few weeks),' the study authors wrote.
SOURCE:
Jorge Sánchez, MD, PhD, with the University of Antioquia, Medellín, Colombia, was the corresponding author of the study, which was published online on June 4 in The Journal of Allergy and Clinical Immunology: In Practice.
LIMITATIONS:
The study did not include children. The calculator needs to be validated on other continents, the authors said.
DISCLOSURES:
This study was supported by the University of Antioquia and Alma Mater de Antioquia Hospital. The authors reported having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Harvard Business Review
an hour ago
- Harvard Business Review
AI in Life Sciences
Download the Report The life sciences industry needs a shot of adrenaline. An aging population and a rise in chronic diseases are fueling the demand for highly accurate medical imaging and diagnostic tools. Pharmaceutical companies and manufacturers are under growing pressure to keep pace with supply and demand for critical medications and medical devices, respectively. Patients, meanwhile, are increasingly demanding personalized health care experiences that cater to their unique needs.
WebMD
2 hours ago
- WebMD
The Surge in Type 1 Diabetes, and the New Ways to Fight It
Aug. 19, 2025 — Cases of type 1 diabetes — an autoimmune condition where the body attacks insulin-producing beta cells — are rising faster than ever, climbing about 42% in since 1990. That's a huge increase in a disease that's expensive, incurable, and still shortens lifespan by more than a decade. But the number of new and emerging treatments is surging too, and experts say we're in the most promising era of type 1 diabetes treatments in history, with new medications that slow the disease's progression, advanced insulin delivery systems, inhalable options, and drugs that improve insulin resistance. It's a shift in the management of a chronic lifelong disease for patients who are often diagnosed in childhood. 'These patients are living much longer than they used to with an improved quality of life,' said Kupper A. Wintergerst, MD, a pediatric endocrinologist and executive director of the Wendy Novak Diabetes Institute. Experts attribute the rise in type 1 cases to a few factors. Genetics play a role in who will get type 1 diabetes, increasing a patient's risk by about 40%. And in people with an increased risk, certain environmental factors may serve to nudge them toward getting the disease. For example, infections in early childhood like mumps, rubella, and influenza B as well as childhood obesity and certain environmental factors like antibiotics overuse, vitamin D deficiency, and the hygiene hypothesis — which suggests that kids who aren't exposed to enough microorganisms in childhood may end up with an overactive immune system — may also be playing a role. Additionally, certain chemicals found in foods and drinking water, including PFAS, dioxins, and arsenic, may jolt inflammation in the body. Once these chemicals build up in the bloodstream, it triggers a chronic inflammatory state, which contributes to the immune system mistakenly attacking and destroying its own insulin-producing beta cells in the pancreas. Over time, this lack of beta cells causes the body to stop making insulin, which starts to raise blood sugar. Researchers are responding with new treatment strategies that leverage a slowed progression of the disease while also more accurately monitoring and regulating blood sugars, which all work to extend lifespan. The number of patients living past 65 has tripled in the last four decades. Slowing Progression of the Disease Type 1 diabetes is usually diagnosed in childhood, though it can develop in adulthood, too. A new medication, called teplizumab (Tzield), has been shown to slow the disease's progression, potentially staving off the disease for two or three years. It's now for patients either before they're diagnosed or early after a diagnosis. Once patients have tested positive for two or more type 1 diabetes-related autoantibodies, they're considered eligible for the medicine. They may also have abnormal blood sugar levels but don't yet have other symptoms of type 1 diabetes like excessive thirst, frequent urination, slowed wound healing, and excessive hunger. The medication works by binding to CD3 proteins on the surface of the white blood cell, helping to block the autoimmune attack. The medication must be started a few weeks or months after diagnosis. While it's not good for all patients, it can be helpful especially for children in staving off this life-altering condition for up to three more years of childhood. 'For patients who are early on in their type 1 disease, this medication can help prolong the beta cell function that is remaining and decrease how much insulin a person needs, depending on when it's used in their disease course,' said Bethany L. Gottesman, MD, a pediatric endocrinologist at Phoenix Children's in Phoenix, Arizona. Patients need to visit a facility that offers infusion services over the weekend. These infusion centers are available throughout the country. You can also contact the TZIELD COMPASS Support Program to find a center near you. Beyond slowing the progression of the disease, the next step would be preserving beta cell function indefinitely, which would prevent the disease. Stem cell-derived beta cells are designed to mimic the function of natural beta cells, restoring function to damaged cells before the damage can to type 1 diabetes. A stem cell-derived treatment called zimislecel has shown promising results in early trials, but it is about a decade away from being available to patients, according to experts. Improved Insulin Delivery Systems Science has revolutionized insulin delivery systems, which now do a much better job of mimicking the pancreas — because they measure sugars beneath the skin and between cells and communicate with the insulin pump. A sensor inserted just beneath the skin measures the interstitial fluid that surrounds cells. After that, software built into the device analyzes the glucose data, sending a message to the insulin pump to deliver insulin through a small needle that penetrates the skin. The data gathered from the cells is transmitted wirelessly to a smartphone or directly to an insulin pump. 'As sugar levels rise or fall, the pump can respond by decreasing or increasing the amount of insulin that's delivered through an algorithm,' said Wintergerst. The algorithm is the computer programming process that tells the glucose monitoring system when more insulin is required, all based on data it's collected on blood sugar in the body as well as other potential inputs such as how many carbohydrates a person consumes. The system can provide extra insulin, for example, if it looks like a patient's blood sugar is going to spike. Still, these insulin delivery systems require the user to input the size of a meal or the amount of carbohydrates that a patient is consuming in order to know whether blood sugar is going to go up or go down in the near future, which can make it more difficult for young children. Experts contend that these more optimized systems help patients deal with type 1 diabetic burnout — when people with diabetes become mentally and physically exhausted as a result of all the demands that are put on them in terms of diet and glucose monitoring. This can be a concerning issue especially among children with diabetes who are new to the disease and must tend to their blood sugar for years to come, said Michael Yafi, MD, director of the Pediatric Endocrinology Division at McGovern Medical School at The University of Texas Health Science Center in Houston. When patients are better able to monitor their condition with ease, they're more likely to be able to stay on track with their blood sugar. This way they'll avoid experiencing the organ damage caused by elevated blood sugars, which over time damages the body's blood vessels and nerves, leading to blurred vision, kidney failure, neuropathy, and early death as the body's systems break down. Inhaled Insulin for Both Kids and Adults The inhaled insulin Afrezza provides rapid delivery of insulin to patients after a meal or after exercise to help stabilize blood sugar levels. People with type 1 diabetes will still need insulin injections or an insulin pump to provide a steady, continuous supply of insulin for longer periods of time, but inhaled insulin can provide additional help for people who need a boost of insulin after eating a meal. It can also reduce the risk of hypoglycemia or low blood sugar after exercise because it's faster acting than the injectable version. For example, in patients who eat carbohydrates before exercise to prevent the low blood sugar that impacts their performance, it can keep the body from overcompensating and causing high blood sugar. Afrezza has already been approved for adults and is likely to be approved for children by the end of 2025, giving patients additional options while also easing some of the needle fatigue. Still, it does have its drawbacks, said Gottesman. 'It's not meant to be used if you have lung disease, and some pediatric patients have asthma. This is also true of older patients with type 1 diabetes, who are more likely to have other lung diseases,' she said. Gottesman added that the insulin only comes in set doses, which for the youngest children might not be appropriate. It's typically not as exact as rapid-acting injections. Inhaled versions of insulin provide a convenience factor for patients. It's also discreet for children who are embarrassed by their condition or don't want to inject themselves with needles in public places like at school. Newer versions of inhaled insulin are also in development, perhaps supplying a version of insulin that's liquid rather than powder, which would reduce respiratory irritation. Aerami Therapeutics has a liquid formulation in development, though it's unclear when it will be ready for the public. GLP-1s for Type 1 Diabetes With Insulin Resistance It might seem obvious: In type 1 diabetes, the problem is lack of insulin production. In type 2, it's insulin resistance – the body still makes insulin but can't use it effectively. But that clear-cut distinction doesn't always hold. Many people, including children, with type 1 diabetes develop insulin resistance, too. Despite lacking natural insulin, their bodies can become resistant to the insulin they do receive, for a number of reasons including excess weight, medications, smoking, puberty, and pregnancy. This overlap has led researchers to explore treatments once thought to be reserved only for type 2 diabetes — including GLP-1 medicines like Ozempic and Wegovy — to help patients drop excess weight and stave off or improve insulin resistance, said Alexandra De Lellis, a nurse practitioner at Parkview Endocrinology in Fort Wayne, Indiana. While type 1 diabetes is mostly an autoimmune disease, insulin resistance can be a secondary issue that causes additional complications when the body resists insulin, causing an increase in the amount of insulin required for patients. This happens when the cells don't react efficiently to insulin as a result of excess body weight, a genetic predisposition, or certain medications. 'Insulin resistance plays a large role especially for type 1 patients diagnosed in adulthood but also those who were diagnosed younger,' said De Lellis. It can be frustrating for these patients who feel like their insulin isn't having the impact it should because the body is resisting it. A study published this year in Frontiers in Endocrinology found that GLP-1s were a 'potential adjunctive therapy in [type 1 diabetes] to reduce weight and improve insulin resistance.' Studies have shown that GLP-1s can reduce blood sugars levels by between by 0.21% and 0.96%, while also reducing weight and the amount of insulin that's required of type 1 patients.
Medscape
3 hours ago
- Medscape
Bladder Cancer: 5 Things to Know
Bladder cancer is the sixth most common cancer in the United States, with approximately 84,870 new cases projected in 2025. This condition is characterized by a high rate of recurrence, particularly among patients with non-muscle-invasive disease, and often requires lifelong surveillance. Bladder cancer is over four times as common in men as in women, with age-adjusted incidence rates of 31.2 and 7.7 per 100,000, respectively, according to SEER data from 2018-2022. This disparity is largely attributed to higher smoking prevalence and increased occupational exposure to carcinogens among men. Most bladder cancers originate in the inner lining of the bladder, with urothelial carcinoma accounting for more than 90% of cases. Although many cases are diagnosed at an early stage, the disease burden remains significant, especially in muscle-invasive and metastatic disease, where outcomes are worse. Diagnosis typically involves cystoscopy, urine cytology, and cross-sectional imaging such as CT or MRI to assess tumor burden and identify local or distant spread. A biopsy obtained during cystoscopy confirms malignancy and provides critical information for tumor staging, which guides treatment decisions. Management options range from transurethral resection and intravesical therapy for non-muscle-invasive disease to radical cystectomy and systemic therapies for more advanced cases. These include immune checkpoint inhibitors such as pembrolizumab and fibroblast growth factor receptor-targeted agents like erdafitinib. Emerging research continues to advance biomarker-guided treatment, noninvasive diagnostics, and personalized medicine aimed at improving clinical outcomes. Here are five things to know about bladder cancer. 1. Artificial Intelligence Is Improving Diagnostic Accuracy and Speed Artificial intelligence (AI) is playing an increasingly important role in bladder cancer diagnostics by enhancing risk stratification and workflow reproducibility. A 2025 ASCO abstract (MP06-18) described a computational histology AI (CHAI) tool that analyzed digitized H&E-stained histopathology slides to assess tumor morphology and stratify recurrence risk in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) based on tumor morphology. The AI model identified patients at significantly higher risk of high-grade recurrence and demonstrated strong prognostic performance across independent cohorts. Beyond risk prediction, AI tools like CHAI highlight the broader potential of integrating AI into pathology workflows. These technologies can reduce diagnostic variability, accelerate turnaround times, and support personalized treatment planning by uncovering histologic patterns that may not be easily detectable by human review. Such advances align with the foundational goals of precision oncology — namely, enabling earlier detection, accurate diagnosis, and personalized treatment guided by individual tumor biology. 2. Mitomycin Offers a Noninvasive Option for Recurrent NMIBC On June 12, 2025, the FDA approved mitomycin intravesical solution as a first-in-class noninvasive treatment for adults with recurrent, low-grade, intermediate-risk NMIBC. Approval was based on robust data from the phase 3 ENVISION trial, which enrolled 228 evaluable patients. At 3 months, 80% of patients achieved a complete response, defined by the absence of visible tumors on cystoscopy and negative urine cytology, with an impressive 82% likelihood of remaining disease-free at 12 months. Mitomycin intravesical solution is delivered via an office-based, bladder-retentive gel system, providing a nonsurgical, bladder-sparing alternative for patients who face recurrent disease and wish to avoid a repeated transurethral resection of bladder tumor procedure. The therapy offers a meaningful treatment paradigm shift: instead of undergoing invasive surgery under anesthesia, patients receive six weekly outpatient instillations of mitomycin, allowing for easier administration and potentially fewer complications. While the FDA advisory committee raised concerns over reliance on single-arm data, FDA reviewers emphasized the significant patient benefit in avoiding repeat surgeries. 3. NECTIN4 Amplification May Help Guide Therapy Selection in Metastatic Urothelial Cancer A growing body of research highlights molecular biomarkers as pivotal tools in guiding therapy for advanced urothelial carcinoma. One biomarker gaining significant attention is NECTIN4 amplification, a genomic alteration commonly observed in advanced and metastatic urothelial carcinoma. Retrospective data from a study by Klümper and colleagues suggest that NECTIN4 gene amplification, identified using a NECTIN4 -specific fluorescence in situ hybridization assay, may serve as a predictive biomarker in metastatic urothelial carcinoma. Among 108 patients with metastatic disease, amplification was observed in approximately 26%. In this study, NECTIN4 amplification was associated with a 96% objective response rate to enfortumab vedotin, an antibody-drug conjugate targeting NECTIN4 , compared with 32% in nonamplified tumors. Patients with amplified tumors also experienced significantly improved overall survival, with a 92% reduction in mortality risk, and longer progression-free survival (12.8 vs 5.6 months). While findings like these suggest that NECTIN4 amplification holds promise as a predictive biomarker for response to enfortumab vedotin, clinical implementation will require prospective validation, standardized testing methods, and further research to determine its utility across diverse treatment settings and patient populations. 4. NIAGARA Trial Supports Perioperative Durvalumab for Muscle-Invasive Bladder Cancer The phase 3 NIAGARA trial investigated perioperative durvalumab in combination with neoadjuvant gemcitabine-cisplatin in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). Results presented at ASCO GU 2025 showed a 32% reduction in event-free survival events and a 25% reduction in overall mortality compared with chemotherapy alone. Importantly, the addition of durvalumab also led to higher pathologic complete response rates (37.3% vs 27.5%) and greater circulating tumor DNA clearance, without delaying or compromising radical cystectomy. These findings support perioperative durvalumab as a potential new standard of care for cisplatin-eligible MIBC. By improving survival outcomes and biomarker-based measures of response, the NIAGARA regimen reflects a precision medicine approach to treatment. Given the FDA's recent approval of this combination, the NIAGARA regimen is well positioned to shift the perioperative treatment paradigm in this setting. 5. Y Chromosome Loss May Influence Immunotherapy Response in Men A growing body of research suggests that loss of the Y chromosome (LOY), a somatic event observed in up to 40% of male patients with bladder cancer, may play a dual role in tumor behavior and immunotherapy sensitivity. LOY has been associated with a more aggressive disease phenotype, including accelerated tumor growth, immune suppression, and CD8+ T cell exhaustion, factors that impair immune surveillance and contribute to poorer outcomes. Paradoxically, this immunosuppressive tumor microenvironment may also increase susceptibility to immune checkpoint inhibitors. In both murine and human models, LOY tumors have shown enhanced responsiveness PD-1/PD-L1 blockade, likely due to the exhausted state of tumor-infiltrating T cells. These findings were further supported by a 2025 study showing that LOY in both cancer and immune cells is associated with worse clinical outcomes and may help stratify patients for immunotherapy trials. While prospective clinical data directly linking LOY to checkpoint inhibitor response in bladder cancer are still emerging, the available evidence highlights LOY as a promising predictive biomarker. Ongoing research aims to validate its utility in guiding treatment decisions and refining immunotherapy strategies for men with urothelial carcinoma.
